Embolization or embolisation refers to the passage and lodging of an embolus within the bloodstream. It may be pathological (in which sense it is also called embolism), for example a pulmonary embolism, or therapeutic, as a hemostatic treatment for bleeding or as a treatment for some types of cancer by deliberately blocking blood vessels to starve the tumor cells.
In the cancer management application, the embolus, besides blocking the blood supply to the tumor, also often includes an ingredient to attack the tumor chemically or with irradiation. When it bears a chemotherapy drug, the process is called chemoembolization. Transcatheter arterial chemoembolization (TACE) is the usual form. When the embolus bears a radiopharmaceutical for unsealed source radiotherapy, the process is called radioembolization or selective internal radiation therapy (SIRT).
Embolization is used to treat a wide variety of conditions affecting different organs of the human body.
The treatment is used to occlude:
- Recurrent coughing up of blood
- Cerebral aneurysm 
- Gastrointestinal bleeding
- Primary post-partum bleeding
- Surgical bleeding
- traumatic bleeding such as splenic rupture or pelvic fracture
The treatment is used to slow or stop blood supply thus reducing the size of the tumour:
- Kidney lesions
- Liver lesions, typically hepatocellular carcinoma (HCC). Treated either by particle infarction or transcatheter arterial chemoembolization (TACE).
- Uterine fibroids
- Arteriovenous malformations (AVMs)
- Juvenile Nasopharyngeal Angiofibroma
Embolization is a minimally invasive surgical technique. The purpose is to prevent blood flow to an area of the body, which can effectively shrink a tumor or block an aneurysm.
The procedure is carried out as an endovascular procedure by an interventional radiologist in an interventional suite. It is common for most patients to have the treatment carried out with little or no sedation, although this depends largely on the organ to be embolized. Patients who undergo cerebral embolization or portal vein embolization are usually given a general anesthetic.
Access to the organ in question is acquired by means of a guidewire and catheter(s). Depending on the organ this can be very difficult and time-consuming. The position of the correct artery or vein supplying the pathology in question is located by digital subtraction angiography (DSA). These images are then used as a map for the radiologist to gain access to the correct vessel by selecting an appropriate catheter and or wire, depending on the 'shape' of the surrounding anatomy.
Once in place, the treatment can begin. The artificial embolus used is usually one of the following:
- Coils: Guglielmi Detachable Coil or Hydrocoil
- Microspheres or Beads
Once the artificial emboli have been successfully introduced, another set of DSA images are taken to confirm a successful deployment.
This section does not cite any sources. (April 2016) (Learn how and when to remove this template message)
Liquid embolic agents - Used for AVM, these agents can flow through complex vascular structures so the surgeon does not need to target his catheter to every single vessel. Onyx is an example for a liquid embolic agent.
- Butyl cyanoacrylate (NBCA) - This agent is a permanent rapidly acting liquid, similar to glues sold under trade names such as "SuperGlue," that will polymerize immediately upon contact with ions. It also undergoes an exothermic reaction which destroys the vessel wall. Since the polymerization is so rapid, it requires a skilled surgeon. During the procedure, the surgeon must flush the catheter before and after injecting the NBCA, or the agent will polymerize within the catheter. The catheter must also be withdrawn quickly or it will stick to the vessel. Oil can be mixed with NBCA to slow the rate of polymerization.
- ethiodol - Made from iodine and poppyseed oil, this is a highly viscous agent. It is usually used for chemoembolizations, especially for hepatomas, since these tumors absorb iodine. The half life is five days, so it only temporarily embolizes vessels.
Sclerosing agents - These will harden the endothelial lining of vessels. They require more time to react than the liquid embolic agents. Therefore, they cannot be used for large or high-flow vessels.
- ethanol - This permanent agent is very good for treating AVM. The alcohol does need some time to denature proteins of the endothelium and activate the coagulation system to cause a blood clot. Therefore, some surgeons will use a balloon occlusion catheter to stop the blood flow and allow time for ethanol to work. Ethanol is toxic to the system in large quantities and may cause compartment syndrome. In addition, the injections are painful.
- ethanolamine oleate - This permanent agent is used for sclerosing esophageal varices. It contains 2% benzyl alcohol, so it is less painful than ethanol. However it does cause hemolysis and renal failure in large doses.
- sotradecol - This agent is used for superficial lower extremity varicose veins. It has been around for a very long time and is a proven remedy. However, it does cause hyperpigmentation of the region in 30% of patients. It is less painful than ethanol.
Particulate embolic agents - These are only used for precapillary arterioles or small arteries. These are also very good for AVM deep within the body. The disadvantage is that they are not easily targeted in the vessel. None of these are radioopaque, so they are difficult to view with radiologic imaging unless they are soaked in contrast prior to injection.
- Gelfoam hemostasis - Temporarily occludes vessels for five weeks. Works by absorbing liquid and plugging the vessel. Composed of water-insoluble gelatin, so the particles may travel distally and occlude smaller capillaries. One way to localize the injection of gelfoam is to make a gelfoam sandwich. A coil is placed at a precise location, then gelfoam is injected and lodged into the coil.
- polyvinyl alcohol (PVA) - These are permanent agents. They are tiny balls 50-1200 um in size. The particles are not meant to mechanically occlude a vessel. Instead they cause an inflammatory reaction. Unfortunately, they have a tendency to clump together since the balls are not perfectly round. The clump can separate a few days later, failing as an embolic agent.
- Embolization microspheres - These are superior permanent or resorbable particulate embolic agents available in different well-calibrated size ranges for precise occlusion. Embolization microspheres may comprise additional functionality such as drug loading and elution capability, specific mechanical properties, imageability or radioactivity
Mechanical occlusion devices - These fit in all vessels. They also have the advantage of accuracy of location; they are deployed exactly where the catheter ends.
- coils - These are used for AVF, aneurysms, or trauma. They are very good for fast-flowing vessels because they immediately clot the vessel. They are made from platinum or stainless steel. They induce clots due to the Dacron wool tails around the wire. The coil itself will not cause mechanical occlusion. Since it is made of metal, it is easily seen in radiographic images. The disadvantage is that large coils can disrupt the radiographic image. The coil may also lose its shape if the catheter is kinked. Also, there is a small risk of dislodging from the deployed location.
- detachable balloon - Treats AVF and aneurysms. These balloons are simply implanted in a target vessel, then filled with saline through a one-way valve. The blood stops and endothelium grows around the balloon until the vessel fibroses. The balloon may be hypertonic relative to blood and hence rupture and fail, or it may be hypotonic and shrink, migrating to a new location.
- Minimally invasive
- No scarring
- Minimal risk of infection
- No or rare use of general anesthetic
- Faster recovery time
- High success rate compared to other procedures
- Preserves fertility and anatomical integrity
- Jiang B, Paff M, Colby GP, Coon AL, Lin LM (September 2016). "Cerebral aneurysm treatment: modern neurovascular techniques". Stroke Vasc Neurol. 1 (3): 93–100. doi:10.1136/svn-2016-000027. PMC . PMID 28959469.
- Chauleur C, Fanget C, Tourne G, Levy R, Larchez C, Seffert P (July 2008). "Serious primary post-partum hemorrhage, arterial embolization and future fertility: a retrospective study of 46 cases". Hum. Reprod. 23 (7): 1553–9. doi:10.1093/humrep/den122. PMID 18460450.
- Whittingham-Jones, P.; Baloch, I.; Miles, J.; Ferris, B (2010). "Persistent haemarthrosis following total knee arthroplasty caused by unrecognised arterial injury". Grand Rounds. 10: 51–54. doi:10.1102/1470-5206.2010.0010 (inactive 2017-01-15). Archived from the original on 2010-10-24.
- Alhamid N, Alterky H, Othman MI (January 2013). "Renal artery embolization for managing uncontrolled hypertension in a kidney transplant candidate". Avicenna J Med. 3 (1): 23–5. doi:10.4103/2231-0770.112791. PMC . PMID 23984264.
- Madoff DC, Hicks ME, Vauthey JN, Charnsangavej C, Morello FA, Ahrar K, Wallace MJ, Gupta S (2002). "Transhepatic portal vein embolization: anatomy, indications, and technical considerations". Radiographics. 22 (5): 1063–76. doi:10.1148/radiographics.22.5.g02se161063. PMID 12235336.
- Gelfoam at Pfizer
- Carretero C, Munoz-Navas M, Betes M, Angos R, Subtil JC, Fernandez-Urien I, De la Riva S, Sola J, Bilbao JI, de Luis E, Sangro B (June 2007). "Gastroduodenal injury after radioembolization of hepatic tumors". The American Journal of Gastroenterology. 102 (6): 1216–20. doi:10.1111/j.1572-0241.2007.01172.x. PMID 17355414.
- Arepally A, Chomas J, Kraitchman D, Hong K (April 2013). "Quantification and reduction of reflux during embolotherapy using an antireflux catheter and tantalum microspheres: ex vivo analysis". Journal of Vascular and Interventional Radiology : JVIR. 24 (4): 575–80. doi:10.1016/j.jvir.2012.12.018. PMID 23462064.